[1]王墨培 综述 马力文* 审校.肌层浸润性膀胱癌新辅助化疗的进展[J].中国微创外科杂志,2021,01(1):65-68.
点击复制

肌层浸润性膀胱癌新辅助化疗的进展()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2021年1期
页码:
65-68
栏目:
文献综述
出版日期:
2021-02-26

文章信息/Info

作者:
王墨培 综述 马力文* 审校
(北京大学第三医院肿瘤化疗与放射病科，北京100191)
文献标志码:
A

参考文献/References:

[1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin,2020,70(1):7-30.
[2]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin,2016,66(2):115-132.
[3]Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscleinvasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol,2014,65(4):778-792.
[4]Wallace DM, Raghavan D, Kelly KA, et al. Neoadjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol,1991,67(6):608-615.
[5]Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med,2003,349(9):859-866.
[6]International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC GenitoUrinary Group, Australian Bladder Cancer Study Group, et al.Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet,1999,354(9178):533-540.
[7]Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol,2004,45(3):297-303.
[8]Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a metaanalysis. Eur Urol,2014,65(2):350-357.
[9]Yin M, Joshi M, Meijer RP, et al. Neoadjuvant chemotherapy for muscleinvasive bladder cancer: a systematic review and twostep metaanalysis. Oncologist,2016,21(6):708-715.
[10]李博.AUA/ASCO/ASTRO/SUO 2017指南解读:非转移肌层浸润性膀胱癌的治疗.泌尿外科杂志(电子版),2017,9(3):58-59,64.
[11]Anan G, Hatakeyama S, Fujita N, et al. Trends in neoadjuvant chemotherapy use and oncological outcomes for muscleinvasive bladder cancer in Japan: a multicenter study. Oncotarget,2017,8(49):86130-86142.
[12]Sherif A. The long perspective in emergence of neoadjuvant chemotherapy for bladder cancer in Ontario, Canadaspace for improvement with regular and organized multidisciplinary team meetings. Transl Androl Urol,2018,7(3):508-510.
[13]Kitamura H, Tsukamoto T, Shibata T, et al. Randomised phase Ⅲ study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscleinvasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol,2014,25(6):1192-1198.
[14]Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscleinvasive bladder cancer. Eur Urol,2015,67(2):241-249.
[15]Kim HS, Jeong CW, Kwak C, et al. Pathological T0 following cisplatinbased neoadjuvant chemotherapy for muscleinvasive bladder cancer: A network metaanalysis. Clin Cancer Res,2016,22(5):1086-1094.
[16]NiedersüssBeke D, Puntus T, Kunit T, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer. Oncology,2017,93(1):36-42.
[17]Arima K, Tochigi H, Sugimura Y, et al. Balloonoccluded arterial infusion as a useful neoadjuvant chemotherapy for bladder cancer. Br J Urol,1997,80(3):417-420.
[18]徐小军,汪灶昆.新辅助介入化疗联合微创手术治疗浸润性膀胱癌.中国微创外科杂志,2014,14(2):138-139,142.
[19]Wahafu W, Liu S, Xu W, et al. The longterm efficacy of oneshot neoadjuvant intraarterial chemotherapy combined with radical cystectomy versus radical cystectomy alone for bladder cancer: a propensityscore matching study. BMC Urol,2019,19:117.
[20]Mason SJ, Downing A, Wright P, et al. Healthrelated quality of life after treatment for bladder cancer in England. Br J Cancer,2018,118(11):1518-1528.
[21]Song YP, McWilliam A, Hoskin PJ, et al. Organ preservation in bladder cancer: an opportunity for truly personalized treatment. Nat Rev Urol,2019,16(9):511-522.
[22]Yap SA,Pugashetti N,Chandrasekar T, et al.The promise and disappointment of neoadjuvant chemotherapy and transurethral resection for muscle invasive bladder cancer: Updated results and longterm followup. Urol Pract,2018: S2352077917301437.
[23]Brant A, Kates M, Chappidi MR, et al. Pathologic response in patients receiving neoadjuvant chemotherapy for muscleinvasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT. Urol Oncol,2017,35(1):34.e17-e25.
[24]Koshkin VS, Barata PC, Rybicki LA, et al. Feasibility of cisplatinbased neoadjuvant chemotherapy in muscleinvasive bladder cancer patients with diminished renal function. Clin Genitourin Cancer,2018,16(4):e879-e892.
[25]Hussain SA, Palmer DH, Lloyd B, et al. A study of splitdose cisplatinbased neoadjuvant chemotherapy in muscleinvasive bladder cancer. Oncol Lett,2012,3:855-859.
[26]Loh JM, Tran AL, Ji L, et al. Baseline glomerular filtration rate and cisplatininduced renal toxicity in urothelial cancer patients. Clin Genitourin Cancer,2018,16(1):90-98.
[27]Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatincontaining chemotherapy. Oncologist,2019,24(4):563-569.
[28]Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE012): a nonrandomised, openlabel, phase 1b study. Lancet Oncol,2017,18(2):212-220.
[29]Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinumtreated locally advanced or metastatic urothelial carcinoma: postprogression outcomes from the phase ⅡIMvigor210 study. Ann Oncol,2017,28(12):3044-3050.
[30]Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as firstline treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a singlearm, multicentre, phase 2 trial. Lancet,2017,389(10064):67-76.
[31]Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscleinvasive urothelial bladder carcinoma (PURE01): An openlabel, singlearm, phase Ⅱ study. J Clin Oncol,2018,36:3353-3360.
[32]Necchi A, Lo Vullo S, Raggi D, et al. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscleinvasive urothelial bladder carcinoma: An openlabel, singlearm, singlecenter, phase 2 study. Urol Oncol,2018,36(1):8.e1-e8.
[33]Culp SH, Dickstein RJ, Grossman HB, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol,2014,191(1):40-47.
[34]Chedgy EC, Douglas J, Wright JL, et al. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscleinvasive bladder cancer. Urol Oncol,2016,34(10):469-476.
[35]Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscleinvasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell,2014,25:152-165.
[36]Seiler R, Ashab H, Erho N, et al. Impact of molecular subtypes in muscleinvasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol,2017,72(4):544-554.

备注/Memo

备注/Memo:
*通讯作者,Email:malw678@126.com
更新日期/Last Update: 2021-04-02